Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02269891
Other study ID # 14NMHB
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2014
Est. completion date September 27, 2018

Study information

Verified date November 2018
Source KGK Science Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness of an herbal combination product called Nu Femme, on menopausal symptoms in peri-menopausal women.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date September 27, 2018
Est. primary completion date September 27, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 55 Years
Eligibility Inclusion Criteria:

- Female of any race between the ages of 40 and 55 years (inclusive)

- Experiencing perimenopause (irregular menstrual cycles (>3 months) or cessation of menstrual period for at least 3 months within the last 12 months) OR women in menopause (cessation of menstrual period for at least 12 months).

- Peri-menopausal women must have an endometrial stripe < 8 mm by ultrasound at screening and menopausal women must have an endometrial stripe < 5 mm. Not required for subjects without an intact uterus.

- Women with an intact cervix must have a pap smear that is normal within 12 months of screening.

- Experiences menopausal transition symptoms such as hot flushes, sweating, sleep disturbance, migraine, anxiety, vaginal dryness and sexual problems.

- Minimum of 4 hot flashes per day or 28 per week

- Total scores of Menopause Rating Scale =17 indicating the menopausal symptoms are moderate or severe

- TSH screening to exclude undiagnosed hyperthyroidism

- Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements.

Exclusion Criteria:

- Women with a positive mammogram

- Significant cardiac history including uncontrolled hypertension (defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems

- Uncontrolled hyperlipidemia

- History or current diagnosis of breast cancer or breast cancer in an identical twin, or any cancer (except non-melanomatous skin cancer) diagnosed less than 5 years prior to randomization. Subjects with other cancers in full remission more than 5 years after diagnosis are acceptable with the exceptions of breast cancer or genital organ cancer (e.g., cervical cancer, uterine cancer, endometrial cancer, or ovarian cancer)

- Uncontrolled diabetes (Type I or Type II)

- Uncontrolled and/or untreated thyroid disorder

- History or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems

- History or current diagnosis of autoimmune conditions, immunodeficiency or gynaecological disease

- Clinically significant mental depression that is not well-controlled in the opinion of the investigator

- Subject has undergone major surgery within the past one year prior to the randomization visit, except cholecystectomy, and appendectomy

- Subject smokes more than 15 cigarettes a day

- History of alcohol or drug abuse within the past year

- Subject has demonstrated non-compliance with treatment while enrolled in other experimental protocols to which the Investigator has knowledge

- Subject has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the Investigator's opinion, to preclude subject's participation in or to complete the study

- History or findings of undiagnosed abnormal vaginal bleeding within the previous two years prior to the randomization visit, including conditions that, in the Investigator's opinion are likely to be the source of unpredictable vaginal bleeding (i.e. leiomyoma or endometrial polyps)

- Subject has uterine fibroids (> 2cm) or endometriosis. This assessment will be based on the size of the uterus of each participant and will be assessed by the Qualified Investigator

- Pregnant, breastfeeding, or planning to become pregnant during the course of the trial

- Positive urine pregnancy test result

- Polycystic ovary syndrome (PCOS)

- History of abnormal Pap smear

- Significant abnormal liver function as defined as AST and/or ALT > 2 x the upper limit of normal (ULN), and/or bilirubin > 2 x the ULN

- eGFR <60

- Bleeding disorders or anaemia of any etiology defined as haemoglobin = 110 g/L

- Subject has taken any of the following medications in the time periods specified prior to the screening visit and during the study

Sex hormones:

Vaginal rings and vaginal creams, ointments or gels 1 week Transdermal or topical 4 weeks DHEA within 24 weeks Natural supplements advertised to have hormonal effects within 4 weeks Oral within 4 weeks Intrauterine progestin implants within 8 weeks Progestin implants and estrogen alone injections within 12 weeks Injected progestin and estrogen or androgen implants or pellets within 24 weeks

Gonadotropin-releasing hormone (GnRH) agonists within 24 weeks

Selective Estrogen Receptor Modulators (SERMs) within 4 weeks

Glucocorticoids - Chronic high dose (= 7.5 mg prednisone per day or equivalent) for the past 12 weeks. Exceptions: Chronic low dose corticosteroid use (< 7.5 mg prednisone per day, or equivalent) is permitted provided the subject has been stabilized on a dose for at least 12 weeks prior to randomization and maintains the current dose and dosing regimen during the study. Acute topical, inhaled, or oral (e.g. dose packs) use is not exclusionary and will be permitted during the course of the study.

Antidepressant and/or antianxiety medications within 4 weeks unless a chronic stable dose has been maintained for greater than 12 weeks. Subject must maintain current dose and dosing regimen during the study. Use of Effexor (Venlafaxine HCl) within 4 weeks is exclusionary. Use of Dixarit (Clonidine HCl) within 2 weeks is exclusionary.

Thyroid or anti-epileptic medications within 12 weeks unless a chronic stable dose has been maintained for greater than 12 weeks prior to randomization. Subjects must maintain current dose and dosing regimen during the study

Use of Prostaglandins within 4 weeks

Other investigational study medications within 4 weeks

Current use of propranolol

Current use of an intrauterine device (IUD)

Use of natural health products, such as primrose oil, black cohosh, soy products, other than vitamin and/or mineral supplements within 4 weeks

- Known allergy or hypersensitivity to study product ingredients

- Subjects on a weight reduction program or a medically supervised diet.

- Unexplained weight loss or weight gain of more than 5 kg in the month prior to randomization

- Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Nu Femme
Combination product of Labisia pumila and Eurycoma longifolia extracts
Other:
Placebo


Locations

Country Name City State
Canada Manna Research - Quebec Levis Quebec
Canada KGK Synergize Inc. London Ontario
Canada Manna Research - Montreal Pointe Claire Quebec
Canada Manna Research - Toronto Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
KGK Science Inc. Biotropics Malaysia Berhad

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Bone markers NTX and BSALP Baseline to week 12
Other Blood safety parameters CBC, electrolytes (Na K CL), glucose, creatinine, BUN, AST, ALT, GGT, bilirubin, Ca, albumin Baseline to week 12
Other Pap smear Histological analysis for abnormal cells Baseline to week 12
Other Pelvic ultrasound To determine changes in endometrial thickness Baseline to week 12
Other Incidence of adverse events Baseline to week 12
Primary Frequency and severity of hot flashes Assessed based on hot flash symptoms score Baseline to week 12
Secondary Frequency and severity of joint pain Assessed based on joint pain symptoms score Baseline to week 12
Secondary Frequency and severity of hot flashes Assessed based on hot flash symptoms score Baseline to week 24
Secondary Frequency and severity of hot flashes Assessed based on hot flash symptoms score Week 12 to week 24
Secondary Frequency and severity of joint pain Assessed based on joint pain symptoms score Baseline to week 24
Secondary Frequency and severity of joint pain Assessed based on joint pain symptoms score Week 12 to week 24
Secondary Health related quality of life Assessed using the Menopause Rating Scale (MRS) Baseline to weeks 3, 6, 12 and 24
Secondary Menopause specific quality of life Assessed using the Menopause Specific Quality of Life questionnaire (MENQOL) Baseline to weeks 3, 6, 12 and 24
Secondary Serum hormone concentrations Estradiol-17b, FSH, LH, total testosterone and free testosterone Baseline to week 12
Secondary Serum Lipid Profile Total cholesterol, HDL-C, LDL-C and triglycerides Baseline to week 12
See also
  Status Clinical Trial Phase
Completed NCT04090957 - Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Phase 3
Completed NCT00003771 - Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Phase 3
Completed NCT00956813 - Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy Phase 3
Completed NCT00068601 - S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Phase 3
Recruiting NCT05414812 - Intervening on Women's Health for Rural Young Breast Cancer Survivors N/A
Completed NCT00026286 - Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Phase 3
Completed NCT00214903 - European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT) Phase 4
Completed NCT05977426 - The Effects of Reiki on Menopausal Symptoms and Depression Levels N/A
Active, not recruiting NCT00079248 - Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer N/A
Completed NCT00031811 - Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer N/A
Recruiting NCT05586724 - Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy Phase 3
Active, not recruiting NCT00764322 - Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen N/A
Completed NCT00179556 - Effects of Soy Isoflavones on Menopausal Hot Flashes Phase 2/Phase 3
Terminated NCT00892268 - Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain Phase 2
Enrolling by invitation NCT04731402 - The Effect of Acupressure, Laughter Yoga and Mindfulness on Menopausal Symptoms and Quality of Life N/A
Completed NCT00454441 - Sleep Quality in CHIMES (MF101) Phase 2
Active, not recruiting NCT04209543 - Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) Phase 3
Recruiting NCT06151028 - An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy
Completed NCT00427245 - Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Phase 3